Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15603789 | 1.00 | PRKCA (0.51) | PRKCACYP1A2 | |
| SCHEMBL18193440 | 1.00 | PRKCA (0.51) | PRKCACYP1A2 | |
| SCHEMBL31238293 | 0.98 | PRKCA (0.53) | PRKCACYP1A2 | |
| SCHEMBL9084549 | 0.90 | PRKCA (0.49) | PRKCACYP1A2 | |
| SCHEMBL10532101 | 0.89 | — | — | |
| SCHEMBL10919331 | 0.89 | — | — | |
| SCHEMBL10532084 | 0.89 | — | — | |
| SCHEMBL3442326 | 0.88 | PRKCA (0.45) | PRKCACYP1A2 | |
| SCHEMBL6149357 | 0.83 | PRKCA (0.41) | PRKCA | |
| SCHEMBL8765011 | 0.83 | PRKCA (0.51) | PRKCACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20190309289-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10370654-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180320170-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2018-11-08 | — | — | US | disclosed |
| US-9944925-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. | 2018-04-17 | — | — | US | disclosed |
| US-20160186168-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2016-06-30 | — | — | US | disclosed |
| EP-2858516-A2 | TASTE MODIFIERS | Givaudan SA (CH) | 2015-04-15 | — | — | EP | disclosed |
| WO-2013186203-A2 | TASTE MODIFIERS | GIVAUDAN SA (CH) | 2013-12-19 | — | — | WO | disclosed |
| US-6787671-B2 | FOR PRODUCTION OF ALDEHYDES, CARBOXYLIC ACIDS, ESTERS, OR KETONES VIA REACTION OF OSMIUM CATALYST AND PEROXYMONOSULFURIC ACID | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2004-09-07 | — | — | US | disclosed |
| US-20030149299-A1 | Catalytic osmium-assisted oxidative cleavage of olefins | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2003-08-07 | — | — | US | disclosed |
| WO-2003060852-A2 | CATALYTIC OSMIUM-ASSISTED OXIDATIVE CLEAVAGE OF OLEFINS | MICHIGAN STATE UNIVERSITY (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149299-A1 | Catalytic osmium-assisted oxidative cleavage of olefins | OXER1, OXSR1, AOX1 | PRKCA 2719/4885CYP1A2 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.